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Mutations in the m.13094TNCMT-ND5 gene have been previously described in three cases of Leigh Syndrome (LS).
In this retrospective, international cohort studywe identiﬁed 20 clinically affected individuals (13 families) and four
asymptomatic carriers. Tenpatientswere deceased at the timeof analysis (median age of deathwas 10years (range:
5·4months−37 years, IQR=17·9 years). Nine patientsmanifestedwith LS, onewithmitochondrial encephalomy-
opathy, lactic acidosis and stroke-like episodes (MELAS), and one with Leber hereditary optic neuropathy. The
remaining nine patients presented with either overlapping syndromes or isolated neurological symptoms. Mito-
chondrial respiratory chain activity analysis was normal in ﬁve out of ten muscle biopsies. We conﬁrmed maternal
inheritance in six families, and demonstratedmarked variability in tissue segregation, and phenotypic expression at
relatively low blood mutant loads. Neuropathological studies of two patients manifesting with LS/MELAS showed
prominent capillary proliferation, microvacuolation and severe neuronal cell loss in the brainstem and cerebellum,
with conspicuous absence of basal ganglia involvement. These ﬁndings suggest that whole mtDNA genome
sequencing should be considered in patientswith suspectedmitochondrial disease presentingwith complex neuro-
logical manifestations, which would identify over 300 known pathogenic variants including the m.13094TNC.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Defects in oxidative phosphorylation (OXPHOS) are an important
cause of human morbidity and mortality, with complex I (NADH-ubi-
quinone oxidoreductase) deﬁciency recognized as the most commonly
observed OXPHOS defect (Rodenburg, 2016). Complex I (NADH: ubi-
quinone oxidoreductase) is the largest component of the oxidative
phosphorylation system (OXPHOS) composed of 45 subunits that, in
supercomplex formation with respiratory chain complexes III and IV,
drives the generation of a transmembrane protein gradient powering
adenosine triphosphate (ATP) synthesis. Complex I requires 14 evolu-
tionary conserved core subunits for its catalytic function: seven
mtDNA-encoded NADH-dehydrogenase (ND) core subunits (ND1-6,
ND4L) and seven nuclear DNA (nDNA) encoded subunits (NDUFV1,
NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7 and NDUFS8), in addition
to 31 supernumerary subunits, whose exact roles are yet to be fully de-
ﬁned (Zhu et al., 2016). TheMT-ND5 gene of complex I, appears to be a
mutational ‘hot spot’ (Bannwarth et al., 2013) and linked to a variety of
clinical phenotypes ranging from single organ involvement, such as iso-
lated exercise intolerance (Downham et al., 2008) or Leber hereditary
optic neuropathy (LHON) (Howell et al., 1993), to multisystem disease
manifesting as renal failure and myopathy (Alston et al., 2010), Leigh
syndrome (LS) (Blok et al., 2007; Kirby et al., 2003), mitochondrial en-
cephalomyopathy, lactic acidosis and stroke-like episodes (MELAS)
(Shanske et al., 2008; Liolitsa et al., 2003), or as a combination of over-
lapping syndromes including LS/MELAS (Blok et al., 2007; Crimi et al.,
2003), MELAS/myoclonic epilepsy and ragged red ﬁbers (MERRF)
(Naini et al., 2005), LHON/MELAS (Pulkes et al., 1999) and LS/MELAS/
LHON (Liolitsa et al., 2003). The limited understanding of the natural
history of disease caused by such mutations presents signiﬁcant chal-
lenges in clinical practice, particularly in relation to pre-symptomatic
genetic testing of at-risk family relatives.
The m.13094TNCmutation, in theMT-ND5 gene, is considered a rare
pathogenic variant that has been previously reported in association
with LS but the full phenotypic spectrum has remained poorly under-
stood (Valente et al., 2009; Ching et al., 2013). We present the clinical,
radiological, and histopathological data of 24 subjects who harbor the
m.13094TNC mutation. We have also studied the neuropathological
changes in two patients with LS/MELAS overlap syndrome, to fully elu-
cidate the spectrum of m.13094TNC-related mitochondrial disease and
to offer guidance on management and genetic counseling.
2. Materials and Methods
2.1. Study Design and Patients
This retrospective, international cohort study was done at the NHS
Highly Specialised Service-funded Mitochondrial Diagnostic Centers in
Newcastle upon Tyne and London, UK. These included patients referred
from four other countries: China, SouthAfrica, Greece and Japan. Eligible
participants were genetically conﬁrmed to harbor them.13094TNCmu-
tation (p.Val253Ala) inMT-ND5 over a 17 year period (January 2000–
October 2017); their maternal family members were traced and exam-
ined whenever possible.
This studywas approved and performed under the ethical guidelines
issued by our institution for clinical studies, and compliedwith the dec-
laration of Helsinki.
2.2. Clinical Presentation and Phenotypic Evaluation
Each patient was assessed by a specialist (pediatrician, adult neurol-
ogist and/or ophthalmologist) at each center, and their medical records
were comprehensively reviewed. The clinical presentation of individual
patients and their family pedigree are provided in Supplemental data
and Supplemental Fig. 1. Where possible, common clinical syndromes
described in mitochondrial disease were assigned (and agreed by all
authors).
2.3. Histopathological and Biochemical Studies
Standard histological (hematoxylin and eosin (H&E) and modi-
ﬁed Gomori Trichome stains), histochemical (cytochrome c oxidase
(COX), succinate dehydrogenase (SDH), and sequential COX–SDH
and biochemical assessments of muscle tissue were performed as de-
scribed elsewhere (Supplemental Table 1). Fresh tissue was ﬁxed in
2.5% glutaraldehyde buffered to pH 7.4 with phosphate buffer and
post-ﬁxed in OsO4 and embedded in Epon LX-112. Ultra-thin sections
were examined in an electron microscope (JEOL⁃1500, Japan) for Pa-
tient 5.
2.4. Molecular Genetics
Extraction of total DNA was performed as per standard procedure.
The whole mitochondrial genome was sequenced, and pyrosequencing
assay was used (Blakely et al., 2013) to screen for and quantify the
m.13094TNC mutation (GenBank Accession number: NC_012920.1)
for 13 patients (Patients 1, 1.1, 1.2, 2, 2.1, 2.2, 2.4, 3, 3.1, 4, 6, 8 and
8.1). The assay could reliably detect a level of N3% ofmutantmtDNA. Re-
striction fragment length polymorphism (RFLP) analysis was performed
to quantify them.13094TNC heteroplasmy level in Patients 5, 12 and 13,
with the sensitivity of ~5% (Valente et al., 2009). The mutant
heteroplasmy level was quantiﬁed using next-generation sequencing
(NGS) for Patients 7, 7.1, 7.2, 9 and 10 (sensitivity N 10%).
2.5. Neuropathological Studies
Neuropathological investigations were performed on postmortem
brain tissues from two patients (patients 1.2 and 8). Cresyl fast violet
(CFV), H&E and Luxol fast blue with H&E counterstain were used on
formalin-ﬁxed parafﬁn-embedded tissues to determine neuronal popu-
lation density and degree of myelination. Immunohistochemistry to de-
termine the expression levels of mitochondrial respiratory chain
subunits, including complex I subunit NADH: ubiquinone oxidoreduc-
tase subunit B8 (NDUFB8) and complex II subunit succinate dehydroge-
nase subunit A (SDHA), were performed on 5 μm thick sections as
previously described (Lax et al., 2012).
2.6. Statistical Analysis
Non-parametric, continuous data were presented as median (range
and inter-quartile range (IQR)). Correlation of mtDNA heteroplasmy
level of different tissues and age of disease onset was examined using
Spearman rank correlation test. Statistical signiﬁcance was determined
at p b 0.05. Data were managed and analyzed with IBM SPSS for Win-
dows version 22.
3. Results
3.1. Patient Cohorts
Clinical features of 24 individuals from 13 families are summarised
in Table 1. The median age of disease onset was 5.5 years (n = 20,
range: 6 weeks to 34 years, IQR = 13 years; the age of onset not
known for two patients). Four individuals were clinically unaffected;
they were ascertained pre-symptomatically due to diagnosis in other
family members. Ten patients (42%) were deceased, and the median
age of death was 10 years (range: 5.4 months to 37 years, IQR =
17.9 years).
Eleven patients presented with distinctive clinical syndromes previ-
ously described in mitochondrial disease. However, the remaining pa-
tients (n = 9) manifested with an isolated neurological symptom or
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overlapping syndromes, of which central nervous system was most
commonly affected (Table 1). Centrally mediated respiratory failure or
apnoea was documented in nine patients (38%) with LS, including an
adult patient who presented at the age of 22 years (Patient 10). Refrac-
tory focal onset seizures with or without evolution to bilateral convul-
sions occurred in eight patients (35%).
3.2. Radiological Imaging
Cranialmagnetic resonance imaging (MRI)was available for analysis
in 17 patients (Table 2, Fig. 1 and Supplemental Fig. 2). The most
common T2/FLuid Attenuation Inversion Recovery (FLAIR)-signal
abnormalities were present in the midbrain (n = 12) and thalamus
(n = 9: bilateral, symmetrical changes; n= 3: unilateral) followed by
pons (n=10) andmedulla (n= 9). Brainstem changes in two patients
(Patients 6 and 8), initially was initially misdiagnosed as a low-grade
glioma, although gadolinium-enhancementwas absent. Subacute corti-
cal and subcortical signal changes were identiﬁed in six patients that
were consistentwith stroke-like lesions. Two patients hadmultiple cor-
tical lesions including lesions within the cerebellar hemispheres (Pa-
tients 1.2 and 5), suggestive of cross cerebellar diaschisis. Cervical
cord lesions were also identiﬁed in six patients.
Signal abnormalities within the basal ganglia, classically seen in LS,
were only identiﬁed in two patients (Patients 11 and 13).
3.3. Histopathological and Biochemical Analyses
Histopathological and histochemical evaluation was normal in most
patients except minor changes detected in the skeletal muscle of three
patients: minor ragged red ﬁbers (n = 1), lipid droplets and abnormal
mitochondrial ultrastructure (n=1) and occasional angular atrophic ﬁ-
bers (n= 1). Mitochondrial respiratory chain activity was measured in
skeletal muscle tissue from 10 patients. One patient demonstrated iso-
lated complex I deﬁciency, one patient with combined complex I and
III deﬁciencies, two patients with combined complex I and IV deﬁcien-
cies and one patient had low complex I and II activity in postmortem tis-
sue, which was caused by signiﬁcant delay in tissue handling. The
remaining six cases demonstrated normal respiratory chain activity
(Supplemental Table 1).
3.4. Molecular Genetics
Thirteen probands were identiﬁed to harbor the m.13094TNCmuta-
tion through whole mtDNA sequencing after screening negative for
common mtDNA point mutations including m.3243ANG, m.8344ANG,
MTATP6, andMTATP8 genes. The mutation was identiﬁed in nine indi-
viduals by direct sequencing of themtDNApointmutation through ped-
igree and segregation analysis. Maternal inheritance of them.13094TNC
mutation was conﬁrmed in six family pedigrees. The m.13094TNC mu-
tation was not detected in the blood of Patient 1 (measured at age
Table 1
Syndromic classiﬁcation and clinical features of individuals with the m.13094TNC mutation (n= 24).
Pedigree
patient
Relation AO/AL* Syndrome Clinical features Heteroplasmy (%)
Sz SLEs Cog Str ON Pt Ap DD At PN LA Cardiac Other B U Mu
1 (F) Proband 17/37* LHON/MELAS + + + − + − − − + + − − − 0 55 n.d.
1·1 (M) Offspring 2 mths/9
mths*
LS − − n.k. − − − + + − n.k. + − − n.d n.d. 65
1·2 (F) Offspring 10/14* MELAS/LS + + + + + + − − + + + − − 46 67 90
2 (F) Proband 12/30 SCA/MELAS + + + − − + − − + + − − − 9 40 35
2·1 (F) Mother n.k./49 Ataxia − − − − − − − − + − − − − 3 22 n.d.
2·2 (F) Maternal
grandaunt
−/74 None − − − − − − − − + − − − Ischaemic
stroke, tremor
0 n.d. n.d.
2·3 (M) Maternal
cousin
4
mths/1.5*
LS n.k. n.k. n.k. n.k. n.k. n.k. + n.k. n.k. n.k. n.k. n.k. − n.d. n.d. n.d.
2·4 (M) Maternal
cousin
5/43 LS-like/SCA − − − + + − − − + − − − − 29 n.d. n.d.
3 (M) Proband 6 wks/5.4
mths*
LS + − n.k. + − + + + − − + − − 76 81 80
3·1 (F) Mother −/20s Unaffected − − − − − − − − − − − − − 19 45 n.d.
4 (M) Proband 4/6* LS − − − + − + + + + − Raised
CSF
HCM Spasticity n.d. n.d. 71
4·1 (F) Mother −/n.k. Unaffected − − − − − − − − − − − n.k. − 4 9 n.d.
5 (F) Proband 13/14* MELAS/LS + + + + − + + − − − + − Myoclonus n.d. n.d. 28
6 (M) Proband 2.25/3* LS − − n.k. + − + + + + − − Brady − 45 n.d. 58
7 (M) Proband 7/21 LHON − − − − + − − − − − − − − 26 n.d. n.d.
7·1 (M) Brother 6/20 Subclinical
ON
− − − − + − − − − − − − − 35 n.d. n.d.
7·2 (F) Mother −/47 Unaffected − − − − − − − − − − − − − 7 n.d. n.d.
8 (F) Proband 34/35* MELAS/LS + + + + − + − − + − − PFO Myoclonus n.d. n.d. 83
8·1 (F) Mother −/70s Unaffected − − − − − − − − − − − − − 0 6 n.d.
9 (F) Proband 27/34 MELAS + + + − – – − − + – + – – 5 n.d. 80
10 (M) Proband 22/24 LS − − − + – + + − + − − LVH NIV B/L INO 38 n.d. 61
11 (M) Proband 2/30 LS – – – + + – + − + – Raised
CSF
– PEG, dystonia,
trachy, facial
weakness
n.d. n.d. n.d.
12 (M) Proband 1/4 LS − − − + − + − + − − + − − n.d. n.d. 41
(Fib)
13 (M) Proband 1/14* LS + − + + − + + + n.k. − + − Trachy, PEG 49 n.d. 52
Total 8/23 6/23 7/20 11/23 6/23 10/23 9/24 6/23 12/22 3/22 9/23 4/22
*=deceased, AO=age of onset, AL=age of last followupor death, Ap=apnoea, At=ataxia, B=blood, B/L INO=bilateral inter-nuclear ophthalmoplegia, Brady=bradycardia, Cog=
cognitive impairment, Dev delay = developmental delay (including motor and speech), F = female, Fib = ﬁbrolast, HCM= hypertrophic cardiomyopathy, HTN = hypertension, LA =
lactic acidosis, LS = Leigh syndrome, LVH = left ventricular hypertrophy, M = male, MELAS = mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, mths =
months, Mu=muscle, n.d.= not done, NIV= non-invasive ventilation, n.k. = not known, ON=optic neuropathy, PEG=percutaneous endoscopic gastrostomy, PFO= patent foramen
ovale, PN = peripheral neuropathy, Psy = neuropsychiatric symptoms such as severe depression, anxiety or personality change, Pt = ptosis, RF = respiratory failure, SCA =
spinocerebellar ataxia, SLE = stroke-like episodes, Str = strabismus, Sz = seizures, trachy = tracheostomy, U = urine, yrs. = years.
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37 years) with a severe, adult-onset MELAS phenotype although was
detected at 51% in urine. Patient 2.2 was presumed an obligate carrier
even though the m.13094TNC mutation was not detectable in blood
(measured at age 74 years). There was no tissue sample available for
testing in Patient 2.3. The asymptomatic mother of patient 3 was dem-
onstrated to harbor the m.13094TNC mutation at mtDNA heteroplasmy
Table 2
Cranial MRI changes associated with the m.13094TNC mutation (n= 17).
Patient
no
Age at
scan
(years)
Brain imaging anomalies Fluctuating/
relapsing-remitting
imaging changes
Cerebral cortex
stroke-like
lesion
Basal
ganglia
Thalamus Cerebellum Brainstem Cervical
cord
Dentate
nuclei
Cortex Atrophy Midbrain Pons Medulla
1 36 P, T (R) − U/L (R) − − + − − − − Yes
1.1 8 mths − − B/L − − − + + + C1–2 n.k.
1.2 13; 14 P, O, H (L) − B/L + + + + + + C1 Yes
2 26; 30 O (R) − U/L (L) − − − − − − − Yes
2.2 66 Δ − − − − − − − − − No
2.4 31 − − B/L + + + + + + − n.k.
3 3 mths − − B/L − − − + + + +* n.k.
4 6 − − − + − − + − + − n.k.
5 13; 14 F (B/L), P (B/L) − B/L − + + + + − C2–6 Yes
6 2.25 − − B/L − − − + + + − No
7 7 − − − − − − − − − − n.k.
8 33 O (R) − B/L − − − + − − − Yes
9 34 O (B/L), P,T,F (L) – − − − − − − − n.k. Yes
10 24 − − − − − − + + + − n.k.
11 22, 23 − + U/L − − + + + + + (upper)
*
Yes
12 1 yr 4
mths
− − B/L − − − + + + n.k. Yes
13 10 − + B/L − − − + + − − No
Total 6/17 2/17 12/17 3/17 3/17 5/17 12/17 10/17 9/17 5/15 8/11
All cortical lesions (including cerebellar cortex) exhibited restricted diffusion. B/L = bilateral, CR = corona radiata, F = frontal lobe, H = hippocampus, L = left, n.k. = not known, O =
occipital lobe, P = parietal lobe, R = right, T = temporal lobe, U/L = unilateral, Δ=Patient 2·2 had a history of clinically and radiologically deﬁned lacunar stroke (internal capsule and
corona radiate), * = the extent of cervical lesion had not been clearly deﬁned.
Fig. 1. Cranial and spineMRI. Axial T2-weighted view of Patient 1·2 showed hyperintensities involving the cortical and subcortical areas of left frontal lobe when she presented with the
ﬁrst stroke-like episode (A); the cranial MRI performed during the subsequent stroke-like episode showed hyperintensities involving the left parietal lobe and right cerebellar cortex,
suggestive of cross cerebellar diaschisis (B) and extensive signal abnormalities in the brainstem (C, coronal view). Axial T2-weighted view of Patient 2 showed an isolated, left
thalamic lesion (D). Axial T2 view (E) showed a discrete signal abnormality in the right cerebellum, and asymmetrical hyperintensities in the medulla in Patient 4. The sagittal T2 view
(F) showed an anterior, long hyperintensity in the cervical cord spanning C2-6 levels in Patient 5, corroborated with the signal abnormalities shown in the axial view (G).
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levels of 19%, 27% and 45% in blood, muscle, and urine respectively
(measured at age 24 years). The quantiﬁcation of mutant mtDNA
heteroplasmy level was not performed in two patients due to no access
to tissue samples (Patient 2.3) and only Sanger sequencing was per-
formed in Patient 11 (the mutant load in muscle appeared higher than
blood; sensitivity N 25%).
There was a statistically signiﬁcant negative correlation between
blood mtDNA heteroplasmy level and age (Spearman rho =−0.883, p
b 0.001; Fig. 2A). Among the patients with mutant mtDNA load quanti-
ﬁed in more than one tissue (n= 12), the mutant heteroplasmy levels
in muscle (65% ± 20%; n = 10) and/or urine (40% ± 27%; n = 8)
were consistently higher than blood (24% ± 22%; n = 16) (Fig. 2B).
The discrepancy between muscle and blood mtDNA heteroplasmy
ranged from 3 to 75% in seven patients; the discrepancy between
urine and blood mtDNA heteroplasmy levels ranged from 5 to 51% in
seven patients. Whole exome sequencing (methods described else-
where (Neveling et al., 2013)) was performed to investigate the cause
of optic neuropathy in Patient 7. This excluded other known causative
genes (including OPA1).
The m.13094TNCmutation load of a number of post-mortem tissues
was analyzed from Patients 1.2 and 13 exemplifying the varied tissue
segregation that is characteristic of this mtDNA mutation (Table 3).
Them.13094TNCmutation loadwas speciﬁcally determined in brain ho-
mogenate samples frompatients 1.2 and 8 demonstrating lowermutant
loadwithin neuronal tissues (median=61%, range: 47–69%) compared
to other tissues despite both manifesting with extensive neurological
sequelae (Table 3).
Muscle (Spearman rho = 0.192, p = 0.62) and urine (Spearman
rho = −0.80, p = 0.20) mutant mtDNA heteroplasmy levels did not
correlate with the age of disease onset. There was no signiﬁcant differ-
ence inmeanmutant heteroplasmy level in different syndromic catego-
ries (p= 0.122).
3.5. Neuropathological Findings
The major neuropathological ﬁndings for patients 1.2 and 8 are
summarised in Supplemental Table 2). In patient 1.2, posterior cerebel-
lar cortex demonstrated multiple areas of necrotic lesions ranging from
atrophy of the molecular layer, Purkinje cell dropout and granule cell
loss (Fig. 3A), to total necrosis of the cerebellar cortex that also affected
the underlying white matter (Fig. 3B). Concerning topographical distri-
bution, lesionsweremost severe in the brainstemnuclei (Fig. 3C andD),
the thalamic and subthalamic nuclei (Fig. 3E and F) and primary visual
cortex (Brodmann area 17) (Fig. 3G). At a microscopic level, changes
such as prominent capillary proliferation, microvacuolation and severe
neuronal loss were frequently observed in ﬁxed cerebral and cerebellar
hemispheres, and right brainstem compatible with LS. Downregulation
of complex I subunit (NDUFB8) was evident in the in the pons and cer-
ebellar cortex of patient 1.2, and lesioned thalamus and occipital cortex
of patient 8 (Supplemental Fig. 3).
4. Discussion
In this study, we have identiﬁed marked clinical heterogeneity with
a continuous spectrum of overlapping symptoms associated with the
m.13094TNC mutation. However within that clinical heterogeneity, at
certain points in the course of disease, several distinct clinical syn-
dromes associatedwithmutations in theMT-ND5 genewere clearly dis-
cernible: early onset LS (38%), late childhood/early adulthood-onset LS/
MELAS overlap syndrome (13%) and LHON (4%) (not previously recog-
nized in association with the m.13094TNC mutation). LS frequently
manifested with a typical illness trajectory including hypotonia, cranial
nerve palsies, cerebellar ataxia, and developmental regression; with re-
lapses in clinical status often triggered by inter-current illness.
Brainstem dysfunction (manifesting as centrally-mediated respiratory
failure and lability in blood pressure), commonly occurred as a pre-
terminal event. Patients with the LS/MELAS overlap syndrome typically
presented with refractory focal seizures and stroke-like lesions (as clas-
sically seen inMELAS). Additional features of brainstem dysfunction, in-
cluding acute-onset ptosis, a complex eye movement disorder and
worsening ataxia (as classically seen in LS) were not infrequent. Neuro-
psychiatric symptoms such as excessive anxiety, lowmood, and hyper-
somnolence, in addition to cognitive impairment were features
accompanying stroke-like episodes. A progressive gait disorder with
truncal ataxia was a prominent clinical feature in three adult patients
(13%), and additional neurological features such as strabismus (Patient
Fig. 2. Heteroplasmy levels of the m.13094TNC mutation. (A) A negative correlation
between age and blood mutant heteroplasmy level. (B) Distribution of mutant
heteroplasmy levels for individual patient. The numbering of X-axis corresponds to the
patient number of Table 1.
Table 3
The m.13094TNC heteroplasmy levels in different post-mortem tissues.
Patient 1.2 Patient 8 Patient 13
Syndrome MELAS/LS MELAS/LS LS
Age of death 14 35 14
Post-mortem tissues
Heart 75% – 64%
Adrenal Gland 96% – –
Liver 83% – 23%
Kidney 83% – 56%
Bladder 90% –
Skeletal muscle 88% – 52%
Intestine 69% – 24%
Lung – – 28%
Frontal lobe 69% 47% –
Hippocampus 67% 52% –
Cerebellum 64% 58% –
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2.4), axonal neuropathy and stroke-like episode (Patient 2) were iden-
tiﬁed. Interestingly, optic neuropathywas the ﬁrst clinicalmanifestation
in four patients (Patients 1, 2.4, 7 and 7.1); however, additional severe
central nervous system (CNS) involvement evolved in two patients (Pa-
tients 1 and 2.4). These ﬁndings highlight that as the disease progressed,
discrete syndromeswere no longer discernible. Indeed, the heterogene-
ity of the neurological manifestations in the m.13094TNC mutation ap-
pears similar to that observed in other mtDNA encoded complex I
gene mutations.
The most common T2/FLAIR signal abnormalities on cranial MRI
were localized to the brainstem (71%), thalamus (71%), cerebral cortex
(35%) and cervical cord (31%) and medial thalamic changes (with re-
stricted diffusion)were identiﬁed in seven out of eight patients present-
ing with refractory epilepsy. Such ﬁndings suggest prolonged seizure
activity (focal status epilepticus) as the underlying pathophysiological
mechanism of the radiological (and clinical) changes observed
(Katramados et al., 2009). MRI abnormalities in cortical and/or subcor-
tical areas, cerebellar hemispheres (crossed cerebellar diaschisis,
which refers to cerebellar hypometabolism is ascribed to functional dis-
connection of the contralateral hemisphere from the cerebral cortex)
(Tien and Ashdown, 1992) corpus callosum, thalami and basal ganglia
have been increasingly reported in cases of isolated seizures, seizure
clusters, and status epilepticus (Katramados et al., 2009). Moreover,
the development of cognitive dysfunction in these patients may be ex-
plained by the observed involvement of the cerebello-thalamo-cortical
pathway (white matter tracts connecting the cerebellar cortex to the
contralateral various cerebral cortices, passing through the superior cer-
ebellar peduncle, red nuclear and the thalamus) (Palesi et al., 2015). T2/
FLAIR signal abnormality involving the brainstem extending into the
upper cervical cordwas identiﬁed in four patients. Interestingly, Patient
5 had quite extensive T2/FLAIR signal changes spanning from C2 to C6,
mimicking a demyelinating disorder but CSF restricted oligoclonal
bands and anti-aquaporin 4 antibodies both tested negative. Whilst MR
imaging ﬁndings are consistent with previously documented changes
in other complex I deﬁcient patients, it is striking that only two patients
with the m.13094TNC mutation had evidence of striatal lesions (Valente
et al., 2009) compared to 90% of complex I cases reported by Lebre et al.
(2011)) These ﬁndings are corroborated by relative preservation of the
striatum and the presence of devastating destruction of the thalami
and brainstem with marked capillary proliferation on autopsy examina-
tion. Whilst symmetrical signal abnormalities in basal ganglia are the
most common radiological ﬁnding in patients affected by LS, lesions
may merely be conﬁned to the brainstem (Leigh, 1951; Rahman et al.,
1996), as was observed in all our cases. This again serves as a reminder
that the diagnosis of LS (including due to MT-ND5 mutations) should
be considered even in the absence of symmetrical basal ganglia lesions.
Fig. 3. Neuropathological features of Patient 1.2 and 8. Patient 1.2: The posterior cerebellar cortex is affected bymultiple necrotic lesions (demarcated by *) demonstrating atrophy of the
molecular layer, Purkinje cell dropout and granule cell loss (A; LFB H&E) and total necrosis of the cortex and underlying white matter (B; LFB H&E). The basis pontis demonstrates a
devastating lesion with total neuronal cell loss (C; red dashed line; LFB H&E). Scale bar = 100 μm. Patient 8: The lower midbrain shows devastated inferior colliculus with prominent
capillary proliferation (arrows), microvacuolation and severe neuronal cell loss (D; H&E). The thalamus (E; LFB H&E) and subthalamic nucleus (F; H&E) are devastated featuring
prominent capillary proliferation (arrows), microvacuolation, severe neuronal cell loss and morphologically normal neurons scattered throughout (arrowhead). The occipital lobes
reveal microvacuolation and laminar necrosis of the cortical layers within Broadmann area 17 (G; LFB H&E) with the underlying white matter demonstrating myelin pallor relative to
otherwise preserved myelin. The cortex features microvacuolation, severe neuronal cell loss and capillary proliferation. Surviving neurons within the inferior colliculus lack complex I
subunit expression (H; NDUFB8 IHC, arrows) while mitochondrial mass is high (I; SDHA IHC, arrows).
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The radiological appearances of patients with LS harboring the
m.13094TNC mutation bear similarities to mitochondrial diseases
caused by autosomal recessive tRNA synthetase mutations, such as
leukoencephalopathy with thalamus and brainstem involvement
and high lactate (LTBL) caused by EARS2 mutations and
leukoencephalopathy with brainstem and spinal cord involvement
and lactate elevation (LBSL) caused by DARS2 mutations (Diodato
et al., 2014). In two of our cases, the radiological diagnosis was thought
to be a space- occupying lesion at presentation. However, the ‘relapsing-
remitting’ course of neurological deﬁcits associated with m.13094TNC-
related mitochondrial disease, coupled with the evolution of signal ab-
normalities on interval brain imaging and demonstration of abnormal
signals in different regions of structurally normal brain on T1 images
(but abnormal cerebral metabolism on MR spectroscopy), should aid
clinicians to discern between the two conditions.
The clinical features of these patients may also overlap at various
stages of the disease with other more common forms of mitochondrial
disease, such as LHON, OPA1, and POLG-related disease, and may
mimic other forms of hereditary ataxia. In addition, m.13094TNC-re-
lated mitochondrial disease may mimic inﬂammatory CNS disorders
such as acute disseminated encephalomyelitis (ADEM),multiple sclero-
sis (MS) and neuromyelitis optica (Patients 5, 6 and 7). Indeed, the link
of anMS-like illness and common LHONmutations iswell recognized in
Harding disease, where imaging appearances are frequently indistin-
guishable from MS (Matthews et al., 2014). More recently, the coinci-
dental occurrence of an MS-like disorder and OPA1mutations in three
unrelated patients has also been reported (Yu-Wai-Man et al., 2016).
We observed that the histochemical changes such as ragged red and
COX deﬁcient ﬁbers, and biochemical analysis of mitochondrial respira-
tory chain activity in muscle tissue, was normal in 60% of the cases pre-
sented here, similar to other point mutations in MT-ND5 (Kirby et al.,
2003; Liolitsa et al., 2003; Crimi et al., 2003). In addition, the quadruple
immunohistochemistry technique could not detect the reduction of
complex I subunit in muscle tissue in one of our patients (Ahmed
et al., 2017), in accordance with the ﬁndings of preferential CNS mani-
festations in association with this mutation. Interestingly, the threshold
level of mutant mitochondrial load necessary to cause symptoms in
these cases appears to be much lower than in mitochondrial tRNA
gene-related disorders associated with severe clinical phenotypes.
However, our ﬁndings corroborate previous ﬁndings in
transmitochondrial cybrid models of the m.13094TNC mutation
(Valente et al., 2009). Furthermore, severe clinical phenotypes associ-
ated with a relatively low mutant load have also been observed in
other common point mutations in the MT-ND5 gene, including the
m.13513G N A mutation, where a mutant load of b50% in muscle has
been reported in association with LS (Kirby et al., 2003) and MELAS
(Shanske et al., 2008). Preliminary pedigree analysis did not initially
prove informative; however, extensive segregation testing conﬁrmed
this to be a maternally inherited genetic disorder. In addition, our ﬁnd-
ings highlight the importance of recognizing that mtDNA disease can
only be deﬁnitively excluded by performing whole mitochondrial ge-
nome sequencing in post-mitotic tissues, such as muscle. In the case of
predictive testing, we would advocate screening for the m.13094TNC
mutation in muscle and/or urine to minimize the chance of false-
negative results. The variable tissue segregation was further evident
and exempliﬁed by the variable mutation load inmultiple tissues at au-
topsy (Patients 1.2 and 13). Intriguingly, the variable phenotypic
threshold effect associated with the m.13094TNC mutation would sup-
port the assertion thatMT-ND5 synthesis is a rate limiting step for com-
plex I activity (Sazanov, 2015), given the relatively low mutant load
resulting in severe phenotypic expression (Blok et al., 2007). Although
we do not have serial measurements of the m.13094TNC mutant load
in blood for individual patients, our data suggest that mutant mtDNA
heteroplasmy level may decline with age, and we would hypothesize
that there is a negative selection of this mutant mtDNA in bonemarrow
over time, as demonstrated in other commoner mtDNAmutations such
asm.3243ANG andm.13513GNA. However, we concede there is a possi-
bility of ascertainment bias in the older individuals with lower mutant
heteroplasmy levels.
Patients 1.2 and 8 had MELAS/LS overlapping syndrome whilst Pa-
tient 13 had LS only. Patient 1.2 predominantlymanifestedwith a child-
hood onset CNS disorder, with no evidence of myopathy (on clinical
examination), cardiomyopathy, renal impairment or hepatic disease.
However, in Patient 1.2, the mutant heteroplasmy levels were much
higher in skeletal muscle (88%), heart (75%), kidney (83%) and liver
(83%) compared to CNS tissues (~67%). Only patient 8 manifested
with stroke-like episodes and subsequently a brainstem crisis in her
30s, yet the mutant mtDNA heteroplasmy levels in CNS tissues (~52%)
were lower than in Patient 1.2. The tissue speciﬁcity of phenotypic ex-
pression in this mutation is intriguing, and the possible underlying rea-
sons require further elucidation yet support the observation that
mutant heteroplasmy level alone does not fully explain clinicalmanifes-
tation (Gorman et al., 2016).
In summary, them.13094TNCmutation exhibits highly variable neu-
rological manifestations and is frequently associated with high disease
burden and early mortality. Cortico-thalamic-cerebellar involvement
appears to be a frequent ﬁnding in these patients compared to other
rare mtDNA mutations, and may serve as a radiological biomarker of
m.13094TNC – related mitochondrial disease. Moreover, our ﬁndings
would suggest m.13094TNC–related mitochondrial disease is perhaps
not as rare as originally thought. We would suggest that consideration
should be given to screening thewholemtDNA genome in clinically rel-
evant tissues, prior to proceeding to whole exome sequencing, in those
who have tested negative for the commonly recognized disease causing
genes and mtDNA point mutations. Once again, the observed clinical
heterogeneity, often apparent lack of maternal inheritance, normal his-
tological and biochemical muscle biopsy ﬁndings, and variability in tis-
sue segregation in these cases, highlights the diagnostic challenges of
mitochondrial disease caused by rare mtDNA variants. We suggest,
these ﬁndings support a better understanding of m.13094TNC –related
syndromes and their inherent clinical trajectory and as such will serve
to aid a more timely diagnosis, inform accurate genetic counseling,
and facilitate tailored therapeutic interventions.
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